PH12014500739B1 - Methods for treating a stroke-related sensorimotor impairment using aminopyridines - Google Patents

Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Info

Publication number
PH12014500739B1
PH12014500739B1 PH1/2014/500739A PH12014500739A PH12014500739B1 PH 12014500739 B1 PH12014500739 B1 PH 12014500739B1 PH 12014500739 A PH12014500739 A PH 12014500739A PH 12014500739 B1 PH12014500739 B1 PH 12014500739B1
Authority
PH
Philippines
Prior art keywords
stroke
aminopyridines
methods
treating
sensorimotor impairment
Prior art date
Application number
PH1/2014/500739A
Other languages
English (en)
Other versions
PH12014500739A1 (en
Inventor
Andrew R Blight
Anthony O Caggiano
Jennifer F Iaci
Tom J Parry
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of PH12014500739A1 publication Critical patent/PH12014500739A1/en
Publication of PH12014500739B1 publication Critical patent/PH12014500739B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PH1/2014/500739A 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines PH12014500739B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18
PCT/US2012/058607 WO2013052575A1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Publications (2)

Publication Number Publication Date
PH12014500739A1 PH12014500739A1 (en) 2014-05-26
PH12014500739B1 true PH12014500739B1 (en) 2019-05-10

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2014/500739A PH12014500739B1 (en) 2011-10-04 2012-10-04 Methods for treating a stroke-related sensorimotor impairment using aminopyridines

Country Status (22)

Country Link
US (2) US20130085167A1 (enExample)
EP (1) EP2766017B1 (enExample)
JP (1) JP6134722B2 (enExample)
KR (1) KR20140084120A (enExample)
CN (2) CN108451953A (enExample)
AR (1) AR088764A1 (enExample)
AU (2) AU2012318719B2 (enExample)
BR (1) BR112014008082A8 (enExample)
CA (1) CA2850635A1 (enExample)
CL (1) CL2014000799A1 (enExample)
CO (1) CO7061067A2 (enExample)
CR (1) CR20140153A (enExample)
EA (1) EA029558B1 (enExample)
HK (1) HK1201204A1 (enExample)
IL (1) IL231809B (enExample)
MX (1) MX354667B (enExample)
PH (1) PH12014500739B1 (enExample)
SG (2) SG10201600410SA (enExample)
TW (1) TWI592156B (enExample)
UA (1) UA114486C2 (enExample)
WO (1) WO2013052575A1 (enExample)
ZA (1) ZA201402432B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014172266A1 (en) * 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
DE102017115701B4 (de) * 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 4−アミノピリジン誘導体及びその酸付加塩
WO1989009600A1 (en) 1988-04-08 1989-10-19 Massachusetts Institute Of Technology Method and composition for treating neurological disorders
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
DE60034110T2 (de) * 1999-02-09 2007-12-06 The Uab Research Foundation, Birmingham Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
CA2403555A1 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP2667869A1 (en) * 2011-01-28 2013-12-04 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
CR20140153A (es) 2014-07-04
EA029558B1 (ru) 2018-04-30
TW201321000A (zh) 2013-06-01
CN104220072B (zh) 2018-04-17
NZ623255A (en) 2016-08-26
AU2018200114A1 (en) 2018-01-25
EA201490562A1 (ru) 2014-08-29
EP2766017B1 (en) 2020-07-01
TWI592156B (zh) 2017-07-21
JP6134722B2 (ja) 2017-05-24
ZA201402432B (en) 2020-08-26
CL2014000799A1 (es) 2014-11-03
HK1201204A1 (en) 2015-08-28
SG11201401248YA (en) 2014-05-29
CN104220072A (zh) 2014-12-17
WO2013052575A1 (en) 2013-04-11
MX354667B (es) 2018-03-15
BR112014008082A2 (pt) 2017-07-18
IL231809B (en) 2019-06-30
AU2012318719A1 (en) 2014-04-17
BR112014008082A8 (pt) 2018-01-16
CN108451953A (zh) 2018-08-28
US20130085167A1 (en) 2013-04-04
AU2012318719B2 (en) 2017-10-19
CA2850635A1 (en) 2013-04-11
UA114486C2 (uk) 2017-06-26
US20160067232A1 (en) 2016-03-10
HK1204965A1 (en) 2015-12-11
EP2766017A1 (en) 2014-08-20
CO7061067A2 (es) 2014-09-19
SG10201600410SA (en) 2016-02-26
JP2014531470A (ja) 2014-11-27
PH12014500739A1 (en) 2014-05-26
AR088764A1 (es) 2014-07-02
KR20140084120A (ko) 2014-07-04
MX2014003997A (es) 2014-07-22
IL231809A0 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
TN2012000414A1 (en) Forms of rifaximin and uses thereof
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
PH12013500577A1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
IN2014DN06104A (enExample)
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX2012006320A (es) Composiciones de amantadina y metodos para su uso.
PH12016500136B1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
PH12014500739B1 (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines
MY174829A (en) Durable treatment with 4-aminopyridine in patients with demyelination
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
SG10201908587PA (en) Treatment regimens
AU2012240388A8 (en) Treatment regimens
MX362111B (es) Un metodo para mejorar la funcion hepatica.
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
HK1221666A1 (zh) 氨基吡啶用於治疗与某些中风类型相关的视觉障碍的方法
UA41936U (ru) Способ лечения крауроза вульвы в детском возрасте
UA104307C2 (ru) Способ продолжительной терапии с применением 4-аминопиридина
UA97741C2 (ru) Способ восстановления кожных покровов при глубоких распространенных ожогах микроаутодермотрансплантатами
UA56354U (ru) Способ лечения рецидивирующего дакриоцистита у детей
UA65523U (ru) Способ лечения больных первичным остеоартрозом с преобладающим поражением коленных суставов и хроническим синовитом
UA54014U (ru) Способ лечения больных хроническим некалькулезным холециститом в сочетании с ожирением